Partnering & Licensing

Trabedersen – a highly promising opportunity in oncology

  • Antisense Pharma develops unique, highly specific antisense molecules targeting tumor-derived proteins, which play a key role in the underlying disease pathology and progression of various tumor types.
  • The lead compound trabedersen, targeting TGF-β2, has demonstrated clinical Proof of Concept (PoC) with remarkable clinical benefit and excellent safety profile in patients with high-grade glioma.
  • A randomized and active-controlled Phase IIb study in recurrent or refractory high-grade glioma has been completed with highly encouraging results. Due to its excellent safety profile and the promising efficacy the company decided to pursue 1st line treatment of GBM in combination with standard of care. Therefore Antisense Pharma plans to conduct a 1st line GBM trial in combination with standard of care.
  • In addition, in other solid tumor types such as pancreatic cancer and malignant melanoma a high therapeutic activity and clinical PoC of trabedersen was shown in a phase I/II trial in heavily pretreated patients. Due to the unprecedented survival benefit and excellent safety profile seen in this Phase I/II trial, a new phase II trial for 2nd line treatment of pancreatic cancer is planned to start in 2012. Additionally a study in 1st line pancreatic cancer patients, in combination with standard chemotherapy, is planned as well.
  • Trabedersen is protected by a solid and long-lasting IP portfolio, which allows the further development of additional indications within the lifecycle of trabedersen. The EMA and the FDA have granted trabedersen orphan drug status for high-grade glioma and pancreatic carcinoma. Orphan drug status will entitle the compound to 10 years of market exclusivity in the EU and 7 years in the USA following marketing authorization.
  • An excellent, highly experienced management team with high scientific, medical, regulatory and commercial skills and know-how steers and controls the clinical development program.
  • There is strong evidence that trabedersen creates a new paradigm in the treatment of high-grade glioma and other aggressive cancer types. Antisense Pharma is seeking a committed partner to further develop, market and sell this compound either on a global scale or in a regional setting.